{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:24:25Z","timestamp":1791685465061,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tapinarof is a topical, aryl\u2010hydrocarbon receptor agonist that has recently received FDA\u2010approval for the treatment of psoriasis. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Beyond good efficacy and fast onset of action in patients with psoriasis, the clinical response to tapinarof is notable for durable remission or near remission, maintained for an average of 130\u2009days beyond treatment discontinuation in patients with psoriasis in phase 3 studies. Tapinarof is usually well tolerated but can induce a follicular inflammatory reaction and dermatitis in some patients. This narrative review covers the historical development of this molecule, safety and efficacy data from clinical trials conducted with various topical formulations, and practical considerations derived from our 15\u2009years of clinical trial experience with the drug.<\/jats:p>","DOI":"10.1111\/jdv.18925","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T07:38:51Z","timestamp":1674891531000},"page":"1168-1174","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Tapinarof for psoriasis and atopic dermatitis: 15\u2009years of clinical research"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6587","authenticated-orcid":false,"given":"R.","family":"Bissonnette","sequence":"first","affiliation":[{"name":"Innovaderm Research Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Saint\u2010Cyr\u00a0Proulx","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jack","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Maari","sequence":"additional","affiliation":[{"name":"Innovaderm Research Inc.  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1128\/aem.61.12.4329-4333.1995"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.2000.tb09234.x"},{"key":"e_1_2_12_4_1","unstructured":"Welichem Biotech Inc. Inventor.Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors. [cited 2001 Jun 14]. US patent WO2001042231."},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04332.x"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.34"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.10.053"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.06.047"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.037"},{"issue":"1656","key":"e_1_2_12_10_1","first-page":"e128","article-title":"Tapinarof cream (Vtama) for psoriasis","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.05.004"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10113176"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.12.013"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14409"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.01.010"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.085"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155382"},{"issue":"2","key":"e_1_2_12_18_1","first-page":"917","article-title":"Coal tar induces AHR\u2010dependent skin barrier repair in atopic dermatitis","volume":"123","author":"Bogaard EH","year":"2013","journal-title":"J Clin Invest"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.1171"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001221"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.005"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.6627"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15052"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00641-4"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.05.1011"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249412"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18925","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18925","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T08:36:14Z","timestamp":1692520574000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1111\/jdv.18925"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18925","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"2022-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}